Home
Cullgen, Inc.

Cullgen, Inc. Market Share Analysis for April 2026

Industry: N/A

Domaincullgen.com

Year Founded2018

Employees51 - 200

Annual Revenue$5M - $10M

Cullgen, Inc.

Cullgen, Inc. (including company regionals)

cullgen.com

See more website traffic and engagement information

Cullgen, Inc. Revenue up to April 2026 is 5M - 10M

revenue generated by Cullgen, Inc. top domains

Cullgen, Inc. top domains revenue over 3 years

Revenue for Cullgen, Inc. top domains

cullgen.com5M - 10M

See more with Sales Intelligence

Total visits to Cullgen, Inc.'s top domains

Understand Cullgen, Inc. market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

cullgen.com2.5K

See more with Sales Intelligence

Avg. visit duration in Cullgen, Inc.'s top domains

Analyze Cullgen, Inc. engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

cullgen.com00:00:20

See more with Sales Intelligence

Avg. pageviews on Cullgen, Inc.'s top domains

See how Cullgen, Inc. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

cullgen.com2.19

See more with Sales Intelligence

Cullgen, Inc. top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Cullgen, Inc.

These are the website technologies, by industry, used by Cullgen, Inc. top domains

Conversion & Analytics (3)

Google Analytics

eCommerce (2)

Swap

Payment & Currencies (2)

Cart Functionality

Comments System (1)

Disqus

More Technologies

6

See all

News & Signals from Cullgen, Inc.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsGyre Therapeutics, Inc. acquires Cullgen Inc..Gyre Therapeutics (GYRE) announced its agreement to acquire Cullgen, a privately-held, clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degrader and degrader antibody conjugate therapies, in an all-stock transaction valued at approximately $300M.

NewsCullgen Inc. attends event J.P. Morgan Healthcare Conference.Cullgen announces Conference participation during J.P. Morgan Healthcare Conference week.

NewsCullgen Inc. partnered with Astellas Pharma Inc on Jan 1st '23.In 2023 Cullgen completed a Series C financing led by AstraZeneca-CICC Venture Capital Partnership, and also announced a strategic partnership with Astellas Pharma Inc.